BIOLASE, INC Form 8-K November 04, 2014

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

# FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	Biolase, Inc.	
-	(Exact name of registrant as specified in its char-	ter)
Delaware	000-19627	87-0442441
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
4 Cromwell, Irvine, California		92618
dress of principal executive offices)		(Zip Code)
Registrant s telephone number, including area code:		949-361-1200
	Not Applicable	
— Fort	ner name or former address, if changed since las	t report

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Edgar Filing: BIOLASE, INC - Form 8-K

## Top of the Form

#### Item 2.02 Results of Operations and Financial Condition.

On November 4, 2014, Biolase, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2014. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

#### Item 9.01 Financial Statements and Exhibits.

- d) Exhibits.
- 99.1 Press Release of Biolase, Inc., dated November 4, 2014.

# Edgar Filing: BIOLASE, INC - Form 8-K

## Top of the Form

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Biolase, Inc.

November 4, 2014 By: Frederick D. Furry

Name: Frederick D. Furry Title: Chief Financial Officer

# Edgar Filing: BIOLASE, INC - Form 8-K

## Top of the Form

## Exhibit Index

Exhibit No.	Description
99.1	Press Release of Biolase, Inc., dated November 4, 2014